Predictors of clinical effectiveness of Hymenoptera venom immunotherapy
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Summary: Background: Treatment failure during venom immunotherapy (VIT) may be associated with a variety of risk factors, of which the relative importance is unknown. Objective: Our aim was to evaluate the association of baseline serum tryptase concentration (BTC), mastocytosis in the skin (MIS) and of other parameters with the frequency of objective systemic reactions during in‐hospital sting challenge (SC). Methods: In this observational retrospective study, we enrolled 1532 patients (1609 cases due to double SC) with established honeybee or vespid venom allergy who had undergone VIT and a subsequent SC. Data were collected on various putative risk factors. Adult‐onset MIS and/or a BTC > 20.0 μg/L was defined as clinical indicators of systemic mastocytosis. Relative rates were calculated with logistic regression models. Results: Ninety‐eight patients (6.4%) presented with MIS and/or BTC > 20.0 μg/L. 104 cases (6.5%) developed objective generalized symptoms during SC. In the absence of MIS, a BTC ≤ 20 μg/L did not increase the risk for VIT failure. The most important factors associated with a worse outcome were ACE inhibitor medication (OR 5.24, 95% CI 1.83–13.00, P < 0.001), honeybee venom allergy (OR 5.09, 95% CI 3.17–8.15, P < 0.001), systemic allergic reaction during VIT (OR 3.07, 95% CI 1.79–5.14, P < 0.001), and a substantial likelihood to suffer from SM (OR 2.74, 95% CI 1.37–5.22, P = 0.003), whereas a double VIT (OR 0.51, 95% CI 0.27–0.90, P = 0.027) and a longer duration of therapy (OR 0.68 per treatment month, 95% CI 0.50–0.93, P = 0.017) reduced the failure rate. Conclusion: The magnitude of therapeutic success correlates with type of venom, duration of therapy, and venom dose. Adult‐onset MIS and/or a BTC > 20 μg/L is a significant, albeit not the strongest determinant for VIT failure. According to its odds ratio, ACE inhibitor therapy appears to be associated with the highest risk for VIT failure.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wood, S. N. (2006) · doi:10.1201/9781420010404 · Cited by 4,953
Valent, P., Akin, C., Escribano, L., Födinger, M., Hartmann, K., Brockow, K., Castells, M., Sperr, W. R., Kluin‐Nelemans, H. C., Hamdy, N. A. T., et al. (2007) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2007.01807.x · Cited by 750
Self-citationValent, P., Akin, C., Arock, M., Brockow, K., Butterfield, J. H., Carter, M. C., Castells, M., Escribano, L., Hartmann, K., Lieberman, P., et al. (2012) · International Archives of Allergy and Immunology · doi:10.1159/000328760 · Cited by 654
Self-citationBonadonna, P., Perbellini, O., Passalacqua, G., Caruso, B., Colarossi, S., Dal Fior, D., Castellani, L., Bonetto, C., Frattini, F., Dama, A., et al. (2009) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2008.11.018 · Cited by 392
New topics in bradykinin research
Maurer, M., Bader, M., Bas, M., Bossi, F., Cicardi, M., Cugno, M., Howarth, P., Kaplan, A., Kojda, G., Leeb‐Lundberg, F., et al. (2011) · Allergy · doi:10.1111/j.1398-9995.2011.02686.x · Cited by 176
Adult-onset mastocytosis in the skin is highly suggestive of systemic mastocytosis
Berezowska, S., Flaig, M. J., Ruëff, F., Walz, C., Haferlach, T., Krokowski, M., Kerler, R., Petat-Dutter, K., Horny, H.-P., & Sotlar, K. (2014) · Modern Pathology · doi:10.1038/modpathol.2013.117 · Cited by 109
Self-citationValent, P., Horny, H.-P., Triggiani, M., & Arock, M. (2011) · International Archives of Allergy and Immunology · doi:10.1159/000323763 · Cited by 50
Self-citation
Cited by
2015 update of the evidence base: World Allergy Organization anaphylaxis guidelines
Simons, F. E. R., Ebisawa, M., Sanchez-Borges, M., Thong, B. Y., Worm, M., Tanno, L. K., Lockey, R. F., El-Gamal, Y. M., Brown, S. G., Park, H.-S., et al. (2015) · World Allergy Organization Journal · doi:10.1186/s40413-015-0080-1 · Cited by 594
EAACI guidelines on allergen immunotherapy: Hymenoptera venom allergy
Sturm, G. J., Varga, E. ‐., Roberts, G., Mosbech, H., Bilò, M. B., Akdis, C. A., Antolín‐Amérigo, D., Cichocka‐Jarosz, E., Gawlik, R., Jakob, T., et al. (2018) · Allergy · doi:10.1111/all.13262 · Cited by 479
Self-citationAnaphylaxis: A 2023 practice parameter update
Golden, D. B. K., Wang, J., Waserman, S., Akin, C., Campbell, R. L., Ellis, A. K., Greenhawt, M., Lang, D. M., Ledford, D. K., Lieberman, J., et al. (2024) · Annals of Allergy, Asthma & Immunology · doi:10.1016/j.anai.2023.09.015 · Cited by 347
Akdis (2020) · doi:10.1111/pai.13189 · Cited by 320
Stinging insect hypersensitivity
Golden, D. B. K., Demain, J., Freeman, T., Graft, D., Tankersley, M., Tracy, J., Blessing-Moore, J., Bernstein, D., Dinakar, C., Greenhawt, M., et al. (2017) · Annals of Allergy, Asthma & Immunology · doi:10.1016/j.anai.2016.10.031 · Cited by 267
Metadata
- Authors
- Ruëff, F., Vos, B., Oude Elberink, J., Bender, A., Chatelain, R., Dugas‐Breit, S., Horny, H. ‐., Küchenhoff, H., Linhardt, A., Mastnik, S., Sotlar, K., Stretz, E., Vollrath, R., Przybilla, B., & Flaig, M.
- Venue
- Clinical & Experimental Allergy
- Publisher
- Wiley
- Published
- 2014-04-16
- Volume
- 44
- Issue
- 5
- Pages
- 736-746
- ISSN
- 0954-7894 (ISSN-L)
- 1365-2222
- OpenAlex
- W1970297017
- Cited by
- 139
- References
- 7
- FWCI
- 9.40
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Predictors of clinical effectiveness of Hymenoptera venom immunotherapy. https://app.cochat.ai/papers/10.1111/cea.12275
- The paper
- Ruëff, F., Vos, B., Oude Elberink, J., Bender, A., Chatelain, R., Dugas‐Breit, S., Horny, H. ‐., Küchenhoff, H., Linhardt, A., Mastnik, S., Sotlar, K., Stretz, E., Vollrath, R., Przybilla, B., & Flaig, M. (2014). Predictors of clinical effectiveness of Hymenoptera venom immunotherapy. Clinical & Experimental Allergy. https://doi.org/10.1111/cea.12275
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.